title: Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?
abstract: We report here a 44-year-old Moroccan man with resectable gastric adenocarcinoma with overexpression of human epidermal growth factor receptor 2 (HER2) by immunohistochemistry who was treated with trastuzumab in combination with chemotherapy in perioperative setting. He received 3 cycles of neoadjuvant chemotherapy consisting of trastuzumab, oxaliplatin, and capecitabine. Afterwards, he received total gastrectomy with extended D2 lymphadenectomy without spleno-pancreatectomy. A pathologic complete response was obtained with a combination of trastuzumab and oxaliplatin and capecitabine. He received 3 more cycles of trastuzumab containing regimen postoperatively.We conclude that resectable gastric carcinoma with overexpression of the c-erbB-2 protein should ideally be managed with perioperative combination of trastuzumab with chemotherapy. Further research to evaluate trastuzumab in combination with chemotherapy regimens in the perioperative and adjuvant setting is urgently needed.
authors.affiliation: Department of Medical Oncology, University Military Hospital; Rabat, 10000, Morocco. sbittiyassir@yahoo.fr
authors.forename: Yassir
authors.initials: Y
authors.lastname: Sbitti
authors.forename: Ismail
authors.initials: I
authors.lastname: Essaidi
authors.forename: Adil
authors.initials: A
authors.lastname: Debbagh
authors.forename: Habiba
authors.initials: H
authors.lastname: Kadiri
authors.forename: Mohamed
authors.initials: M
authors.lastname: Oukabli
authors.forename: Yassine
authors.initials: Y
authors.lastname: Moussaid
authors.forename: Khaoula
authors.initials: K
authors.lastname: Slimani
authors.forename: Mohamed
authors.initials: M
authors.lastname: Fetohi
authors.forename: Hakim
authors.initials: H
authors.lastname: Elkaoui
authors.forename: Abderrahmane
authors.initials: A
authors.lastname: Albouzidi
authors.forename: Mohamed
authors.initials: M
authors.lastname: Mahi
authors.forename: Abdelmounaim Ait
authors.initials: AA
authors.lastname: Ali
authors.forename: Mohamed
authors.initials: M
authors.lastname: Ichou
authors.forename: Hassan
authors.initials: H
authors.lastname: Errihani
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069287:Capecitabine; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D005743:Gastrectomy; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D019990:Perioperative Care; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069287:Capecitabine; D003841:Deoxycytidine; D005472:Fluorouracil; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab